Supported by experts in epitranscriptomics

 
SAB.jpg
 

Gotham was founded in 2017 based upon the ground-breaking work of its co-founder, Professor Samie Jaffrey, a pioneer in the field of epitranscriptomics. In addition to that, the company has attracted a number of key opinion leaders in the space.

founder.png
green.png

Our Scientific Advisory Board consist of:

Dr. Samie Jaffrey

Weill Medical College of Cornell University & Co-founder of Gotham Therapeutics

Dr. Samie Jaffrey is the Greenberg-Starr Professor in the Department of Pharmacology at the Weill Cornell Medical College.  He received an M.D. and Ph.D. in 1999 from Johns Hopkins School of Medicine where he also conducted postdoctoral research. 

Dr. Jaffrey’s work has fundamentally advanced our understanding of RNA biology and gene regulation.  His lab developed genetically encoded fluorescent RNAs for imaging RNA localization and trafficking in live cells, including the Spinach-tagged RNAs. He has extended this technology to create a new class of genetically encoded biosensors composed of RNA that allows signaling molecules to be imaged in living cells.  Most recently, he has helped to launch the field of “epitranscriptomics,” which relates to the diverse nucleotide modifications that impact the fate and function of mRNA and long noncoding RNAs in cells. Dr. Jaffrey’s transcriptome-wide mapping of N6-methyladenosine (m6A) in 2012 revealed that m6A is a pervasive modification in the transcriptome, thereby identifying this modification as a fundamentally novel form post-transcriptional mRNA regulation.  Since this seminal study, Dr. Jaffrey mapped dimethyladenosine (m6Am) and established functions of m6A and m6Am as well as m6A and m6Am reader, writer, and eraser proteins.

Dr. Jaffrey’s is an elected member of the American Society for Clinical Investigation, and the recipient of the 2017 John J. Abel Award in Pharmacology, Klingenstein Neuroscience Award, Irma T. Hirschl Scholar Award, the McKnight Foundation Technology Development Award, NIH EUREKA Award, the NIH Director’s Transformative R01 Award, the 2013 Blavatnik Award for Young Scientists, and the 2014 American Society for Biochemistry and Molecular Biology Young Investigator Award.


Schragi-Schwartz.png

Dr. Schraga Schwartz

The Weizmann Institute of Science

Dr. Schraga Schwartz is currently group leader at the Department of Molecular Genetics at the Weizmann Institute of Science. His lab focuses on deciphering the roles played by post-transcriptional modifications on RNA. By combining molecular approaches with tailored computational analyses, Dr. Schwartz’s lab has pioneered methodologies allowing the systematic mapping and quantification of diverse RNA modifications and is currently focusing on exploring their roles and mechanisms of action. Before that, he spent four years as a post-doc at the Broad Institute under the joint supervision of Aviv Regev and Eric Lander.


Andrew Mortlock

CSO, Acerta Pharma / VP Oncology Projects and Alliances, AstraZeneca

Dr. Andrew Mortlock is acting in a dual role as CSO of Acerta Pharma, AstraZeneca’s “Hematologic Oncology Center of Excellence”, and as Vice President, Global Oncology Combinations, IMED Oncology at AstraZeneca, where he is responsible for the development of combinations and innovative oncology trials. Over 25 years in roles of increasing responsibility at AstraZeneca, he was previously responsible for AstraZeneca’s small molecule oncology projects from start of lead optimization through to the end of Phase IIb clinical studies. With a strong pre-clinical background, he previously led the Oncology research group at Alderley Park (UK) and Reims (France) which included chemistry, bioscience and drug metabolism. He brings a wealth of medicinal chemistry, global development and project leadership experience involving kinase, protease, integrin, GPCR, nuclear hormone receptor and protein-protein interaction targets.

Dr. Mortlock holds a first degree in chemistry and a PhD in organic chemistry from the University of Oxford and carried out post-doctoral work at the University of California, Berkeley. He has been an author on more than 50 scientific papers, patents and presentations.


Jorge DiMartino
MD, PhD

Vice President, Translational Development Oncology, Celgene

Jorge DiMartino M.D., Ph.D. is Vice President, Translational Development Oncology at Celgene in San Francisco. He joined Celgene in 2011 as a clinical lead for early stage oncology clinical programs. In 2013, he assumed an additional leadership role directing the Translational Research Laboratories at the Celgene’s San Francisco site and in 2015, Jorge was chosen to lead the establishment of the Epigenetics Thematic Center of Excellence, a fully integrated unit driving Drug Discovery through Clinical Proof of Concept efforts around epigenetic targets in cancer and inflammation. He has also played a key role in a number of external collaborations with partner companies including Oncomed, Epizyme, Agios, Forma and the Leukemia Lymphoma Society.

Prior to joining Celgene, Jorge was a Group Medical Director at Genentech in the Oncology Exploratory Clinical Development group.  At Genentech, he led the early clinical development of the Hedgehog Pathway inhibitor, vismodegib, and managed a group of Medical Directors working on a diverse array of targeted small molecules as well as naked and armed antibodies from pre-IND through Phase II.

Jorge received his Ph.D. in Immunology from Cornell University Graduate School of Medical Sciences, and his M.D. from University of California San Diego.  He completed a residency in Pediatrics and a fellowship in Pediatric Hematology/Oncology, both at Stanford University School of Medicine where he continues to see patients in pediatric oncology as a member of the Adjunct Clinical Faculty.